文献速递心脑血管急症

长春西汀作为急性缺血性卒中神经保护剂的安全性与疗效:系统评价与Meta分析

Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
PubMed 文献 · Neurocrit Care · 2022-04-29
一句话结论长春西汀在急性缺血性卒中急性期可能降低残疾(1个月RR 0.80、3个月RR 0.67),但证据不足以提示降低病死率,尚不足以推荐常规使用。

该系统评价与Meta分析检索电子数据库,纳入4项安慰剂对照随机对照试验,长春西汀组601例、安慰剂组236例急性缺血性卒中患者。结果显示,长春西汀组死亡或显著残疾人数在1个月和3个月均低于安慰剂组(RR 0.80,95%CI 0.65-0.99,P=0.04;RR 0.67,95%CI 0.48-0.92,P=0.02),残疾程度(SMD 0.49,95%CI 0.03-0.95,P=0.001;SMD 1.22,95%CI 0.23-2.24,P=0.04)及简易精神状态检查评分较基线变化(加权均数差0.92,95%CI 0.02-1.82,P=0.04)也优于安慰剂组。作者认为长春西汀在急性期使用在降低残疾方面有一些有前景的疗效,但现有证据不足以提示其降低病死率,在推荐对所有急性缺血性卒中患者常规给药之前,需要更多足够样本量的双盲安慰剂对照随机对照试验。

要点

  • 纳入4项安慰剂对照RCT,长春西汀组601例、安慰剂组236例急性缺血性卒中患者。
  • 1个月死亡或显著残疾:长春西汀组低于安慰剂组,RR 0.80(95%CI 0.65-0.99),P=0.04。
  • 3个月死亡或显著残疾:长春西汀组低于安慰剂组,RR 0.67(95%CI 0.48-0.92),P=0.02。
  • 1个月残疾程度SMD 0.49(95%CI 0.03-0.95,P=0.001),3个月SMD 1.22(95%CI 0.23-2.24,P=0.04),均优于安慰剂组。
  • 简易精神状态检查评分较基线变化:加权均数差0.92(95%CI 0.02-1.82,P=0.04),长春西汀组优于安慰剂组。

适用人群与场景

  • 急性缺血性卒中患者,来自4项安慰剂对照随机对照试验,长春西汀组601例、安慰剂组236例。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,纳入4项安慰剂对照随机对照试验,长春西汀组601例、安慰剂组236例急性缺血性卒中患者。
  • 主要终点:1个月死亡或显著残疾人数长春西汀组低于安慰剂组,RR 0.80(95%CI 0.65-0.99),P=0.04;3个月死亡或显著残疾人数长春西汀组低于安慰剂组,RR 0.67(95%CI 0.48-0.92),P=0.02。
  • 次要终点:1个月残疾程度长春西汀组低于安慰剂组,SMD 0.49(95%CI 0.03-0.95),P=0.001;3个月残疾程度长春西汀组低于安慰剂组,SMD 1.22(95%CI 0.23-2.24),P=0.04。
  • 次要终点:简易精神状态检查评分较试验入组时基线的变化,长春西汀组优于安慰剂组,合并加权均数差0.92(95%CI 0.02-1.82),P=0.04。
  • 异质性评估使用Higgins和Thompson的I²法,I²>50%时使用随机效应模型,其他参数使用固定效应模型;发表偏倚用Egger检验评估。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入4项安慰剂对照随机对照试验;偏倚风险采用Cochrane协作组随机对照试验偏倚风险评估工具判定。
  • 作者结论:长春西汀在急性期用于缺血性卒中患者在降低残疾方面有一些有前景的疗效,但现有证据不足以提示其降低病死率。
  • 局限:作者指出在推荐对所有急性缺血性卒中患者常规给予长春西汀之前,需要更多足够样本量的双盲、安慰剂对照随机对照试验。

对床旁实践的改变

  • 作者认为长春西汀在急性缺血性卒中急性期使用在降低残疾方面有一些有前景的疗效,但现有证据不足以提示其降低病死率。
  • 作者建议在推荐对所有急性缺血性卒中患者常规给药之前,需要更多足够样本量的双盲、安慰剂对照随机对照试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Vinpocetine as a neuroprotective agent is effective in acute ischemic stroke in some randomized controlled trials (RCTs). Since the last systematic review has been published in 2008, which didn't find conclusive evidence favoring its use, two more RCTs have also been completed.

METHODS: Relevant electronic databases were searched with a suitable combination of Medical Subject Headings terms to detect publications describing RCTs exploring the safety and efficacy of vinpocetine in patients with acute ischemic stroke. The risk of bias was determined by using the Cochrane Collaboration's tool for assessing the risk of bias in RCTs after full-text review and relevant data extraction. Higgins and Thompson's I2 method was used to assess heterogeneity in studies. The presence of publication bias was assessed by Egger's test. We used a random effect model when I2 was more than 50% and a fixed-effect model for other parameters.

RESULTS: Four placebo-controlled RCTs enrolling a total of 601 and 236 patients in vinpocetine and placebo groups, respectively, were included. The number of patients with death or significant disability was lower in the vinpocetine group than that in the placebo group at both 1 and 3 months (relative risk 0.80, 95% confidence interval [CI] 0.65-0.99 and relative risk 0.67, CI 0.48-0.92, p = 0.04 and 0.02, respectively). The degree of disability in participants at 1 month and 3 months was also lower in vinpocetine group than that in the placebo group (standardized mean difference (SMD) 0.49, 95% CI 0.03-0.95 and SMD 1.22, CI 0.23-2.24, p = 0.001 and 0.04, respectively). Change in mini-mental state examination score compared with baseline at trial enrolment was also better in the vinpocetine group than in the placebo group (pooled weighted mean difference 0.92, 95% CI 0.02-1.82, p = 0.04).

CONCLUSIONS: Vinpocetine has some promising efficacy in patients with ischemic stroke when used in the acute stage in reducing the disability, but presently there is not enough evidence to suggest that it also reduces case fatality. More double-blind, placebo-controlled RCTs of adequate sample size are needed before making recommendations for the routine administration of vinpocetine for all patients with acute ischemic stroke.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Panda PK, Ramachandran A, Panda P, et al. Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Neurocrit Care. 2022. PMID: 35488169. doi:10.1007/s12028-022-01499-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。